Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
15.07
-0.26 (-1.70%)
At close: Jun 27, 2025, 4:00 PM
15.02
-0.05 (-0.33%)
After-hours: Jun 27, 2025, 7:54 PM EDT
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,811 employees as of March 31, 2025. The number of employees increased by 763 or 2.82% compared to the previous year.
Employees
27,811
Change (1Y)
763
Growth (1Y)
2.82%
Revenue / Employee
$136,989
Profits / Employee
$23,794
Market Cap
12.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 27,811 | 763 | 2.82% |
Mar 31, 2024 | 27,048 | 1,185 | 4.58% |
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RDY News
- 22 days ago - Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
- 23 days ago - Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - Business Wire
- 6 weeks ago - Dr. Reddy's Continues To Be A Good Buy At Current Valuation - Seeking Alpha
- 7 weeks ago - Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Dr. Reddy's Q4 & Full Year FY25 Financial Results - Business Wire
- 2 months ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha
- 3 months ago - Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia - PRNewsWire
- 3 months ago - Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - Business Wire